http://www.cas.org/support/stngen/stndoc/properties.html

=> e perfluorocarbon
E1 4 PERFLUOROCAPRYLATE/BI
E2 4 PERFLUOROCAPRYLIC/BI
E3 2 --> PERFLUOROCARBON/BI
E4 1 PERFLUOROCARBONS/BI
E5 2 PERFLUOROCOAT/BI
E6 11 PERFLUOROCT/BI
E7 2 PERFLUOROCTAN/BI
E8 1 PERFLUOROCTANAMID/BI
E9 1 PERFLUOROCTANAMIDOX/BI
E10 1 PERFLUOROCTANAMIDOXIME/BI
E11 1 PERFLUOROCTANE/BI
E12 1 PERFLUOROCTANESULFON/BI

=> s e1-e12
4 PERFLUOROCAPRYLATE/BI
4 PERFLUOROCAPRYLIC/BI
2 PERFLUOROCARBON/BI
1 PERFLUOROCARBONS/BI
2 PERFLUOROCOAT/BI
11 PERFLUOROCT/BI
2 PERFLUOROCTAN/BI
1 PERFLUOROCTANAMID/BI
1 PERFLUOROCTANAMIDOX/BI
1 PERFLUOROCTANAMIDOXIME/BI
1 PERFLUOROCTANE/BI
1 PERFLUOROCTANESULFON/BI
L1 26 (PERFLUOROCAPRYLATE/BI OR PERFLUOROCAPRYLIC/BI OR PERFLUOROCARBO
N/BI OR PERFLUOROCARBONS/BI OR PERFLUOROCOAT/BI OR PERFLUOROCT/B
I OR PERFLUOROCTAN/BI OR PERFLUOROCTANAMID/BI OR PERFLUOROCTANAM
IDOX/BI OR PERFLUOROCTANAMIDOXIME/BI OR PERFLUOROCTANE/BI OR
PERFLUOROCTANESULFON/BI)

=> fil caplus biosis medline uspatful embase
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 62.26 62.47

FILE 'CAPLUS' ENTERED AT 13:14:28 ON 12 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'BIOSIS' ENTERED AT 13:14:28 ON 12 FEB 2008

FILE 'MEDLINE' ENTERED AT 13:14:28 ON 12 FEB 2008

FILE 'USPATFULL' ENTERED AT 13:14:28 ON 12 FEB 2008

FILE 'EMBASE' ENTERED AT 13:14:28 ON 12 FEB 2008

=> s l1 or (perfluor?)
L2 143119 L1 OR (PERFLUOR?)

<------User Break------>

<------User Break------>

=> s l2 and (emulsion?)
L3 25249 L2 AND (EMULSION?)

=> s l3 and (nerv? or endocrin?)
L4 3019 L3 AND (NERV? OR ENDOCRIN?)

=> s l4 and (capillar?)
L5 820 L4 AND (CAPILLAR?)

=> s l5 and (skin(p)capillar?)
L6 70 L5 AND (SKIN(P) CAPILLAR?)

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7 70 DUP REM L6 (0 DUPLICATES REMOVED)

=> s l7 and (py<=2005)
3 FILES SEARCHED...
L8 50 L7 AND (PY<=2005)

=> d ibib ab 1-
YOU HAVE REQUESTED DATA FROM 50 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:331347 USPATFULL <<LOGINID::20080212>>

TITLE: Controlling angiogenesis with anabaseine analogs
INVENTOR(S): Kem, William R., Gainesville, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005288333	A1	20051229 <--
APPLICATION INFO.:	US 2005-147996	A1	20050608 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-577990P	20040608 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AKERMAN SENTERFITT, P.O. BOX 3188, WEST PALM BEACH, FL,
33402-3188, US
NUMBER OF CLAIMS: 63
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 3279
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds controlling angiogenesis and vasculogenesis. In particular, induction of angiogenesis to promote growth of new vasculature by the use of anabaseine agonists and to the reduction of pathological angiogenesis by the use of anabaseine antagonists.

L8 ANSWER 2 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:274051 USPATFULL <<LOGINID::20080212>>
TITLE: Compositions and methods for topical delivery of oligonucleotides
INVENTOR(S): Dokka, Sujatha, San Marcos, CA, UNITED STATES
Cooper, Scott, Petaluma, CA, UNITED STATES
Kelly, Susan, San Diego, CA, UNITED STATES
Hardee, Greg, San Diego, CA, UNITED STATES
Karras, James G., San Marcos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005238606	A1	20051027 <--
APPLICATION INFO.:	US 2005-112451	A1	20050421 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-565244P	20040423 (60)
	US 2004-592577P	20040729 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: COZEN O'CONNOR, P.C., 1900 MARKET STREET, PHILADELPHIA,
PA, 19103-3508, US
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1792
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions and methods which enhance the delivery of nucleic acids and other nucleosidic moieties via topical routes of administration. The invention relates to the use of an aqueous solution to preferentially deliver nucleic acids preferentially to hair follicles. The invention relates to a method of inhibiting hair growth comprising administration of a nucleic acid preferentially to a hair follicle.

L8 ANSWER 3 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:240095 USPATFULL <<LOGINID::20080212>>
TITLE: Polymer compositions and methods for their use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005208095	A1	20050922 <--
APPLICATION INFO.:	US 2004-996354	A1	20041122 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-586861P	20040709 (60)
	US 2004-566569P	20040428 (60)
	US 2003-526541P	20031203 (60)
	US 2003-525226P	20031124 (60)
	US 2003-523908P	20031120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 101
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 34089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 4 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:226572 USPATFULL <<LOGINID::20080212>>
TITLE: Polymer compositions and methods for their use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A E., North Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005196421	A1	20050908	<--
APPLICATION INFO.:	US 2004-1417	A1	20041201	(11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-611077P	20040917 (60)
	US 2004-586861P	20040709 (60)
	US 2004-566569P	20040428 (60)
	US 2003-526541P	20031203 (60)
	US 2003-525226P	20031124 (60)

US 2003-523908P 20031120 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 100
EXEMPLARY CLAIM: 1-7300
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 34222
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 5 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:220596 USPATFULL <<LOGINID::20080212>>
TITLE: Medical implants and anti-scarring agents
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

NUMBER	KIND	DATE
PATENT INFORMATION: US 2005191331	A1	20050901 <--
APPLICATION INFO.: US 2004-1419	A1	20041130 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER	DATE
PRIORITY INFORMATION: US 2003-518785P	20031110 (60)
US 2003-523908P	20031120 (60)
US 2003-524023P	20031120 (60)
US 2003-525226P	20031124 (60)
US 2003-526541P	20031203 (60)
US 2004-586861P	20040709 (60)
US 2004-578471P	20040609 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 178
EXEMPLARY CLAIM: 1-2104
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 56419
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 6 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:215570 USPATFULL <<LOGINID::20080212>>
TITLE: Cell proliferation inhibitors
INVENTOR(S): Li, Qun, Libertyville, IL, UNITED STATES
Sham, Hing, Mundelein, IL, UNITED STATES
Woods, Keith W., Libertyville, IL, UNITED STATES
Steiner, Beth A., Remington, IN, UNITED STATES
Gwaltney, Stephen L. II, Lindenhurst, IL, UNITED STATES
Barr, Kenneth J., San Francisco, CA, UNITED STATES
Imade, Hovis M., Chicago, IL, UNITED STATES
Rosenberg, Saul, Grayslake, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005187246	A1	20050825 <--
APPLICATION INFO.:	US 2005-109017	A1	20050419 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-301427, filed on 21 Nov 2002, PENDING Division of Ser. No. US 2000-579705, filed on 26 May 2000, GRANTED, Pat. No. US 6521658

	NUMBER	DATE

PRIORITY INFORMATION: US 1999-136542P 19990528 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROBERT DEBERARDINE, ABBOTT LABORATORIES, 100 ABBOTT
PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008, US
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 3054
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having formula (I) ##STR1## inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

L8 ANSWER 7 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:215464 USPATFULL <<LOGINID::20080212>>
TITLE: Polymer compositions and methods for their use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005187140	A1	20050825 <--
APPLICATION INFO.:	US 2004-408	A1	20041129 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-586861P	20040709 (60)
	US 2004-566569P	20040428 (60)
	US 2004-611077P	20040917 (60)
	US 2003-526541P	20031203 (60)
	US 2003-525226P	20031124 (60)

US 2003-523908P 20031120 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 103
EXEMPLARY CLAIM: 1-5846
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 34103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 8 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:214572 USPATFULL <<LOGINID::20080212>>
TITLE: Polymer compositions and methods for their use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005186244	A1	20050825 <--
APPLICATION INFO.:	US 2004-1790	A1	20041202 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-611077P	20040917 (60)
	US 2004-586861P	20040709 (60)
	US 2004-566569P	20040428 (60)
	US 2003-526541P	20031203 (60)

US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 103
EXEMPLARY CLAIM: 1-8540
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 34060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 9 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:212068 USPATFULL <<LOGINID::20080212>>
TITLE: Polymer compositions and methods for their use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005183731	A1	20050825 <--
APPLICATION INFO.:	US 2004-6908	A1	20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-611077P	20040917 (60)
	US 2004-586861P	20040709 (60)
	US 2004-566569P	20040428 (60)

US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1-8061
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 34032
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 10 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:212065 USPATFULL <<LOGINID::20080212>>
TITLE: Medical implants and anti-scarring agents
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005183728	A1	20050825	<--
APPLICATION INFO.:	US 2004-7836	A1	20041207 (11)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-518785P	20031110 (60)
	US 2003-523908P	20031120 (60)
	US 2003-524023P	20031120 (60)
	US 2003-525226P	20031124 (60)
	US 2003-526541P	20031203 (60)
	US 2004-586861P	20040709 (60)
	US 2004-578471P	20040609 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 178
EXEMPLARY CLAIM: 1-3411
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 56413
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 11 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:209978 USPATFULL <<LOGINID::20080212>>
TITLE: Polymer compositions and methods for their use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005182463	A1	20050818 <--
APPLICATION INFO.:	US 2004-1788	A1	20041202 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE

---------- --------
PRIORITY INFORMATION: US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 125
EXEMPLARY CLAIM: 1-8059
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 34070
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 12 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:209494 USPATFULL <<LOGINID::20080212>>
TITLE: Medical implants and anti-scarring agents
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

NUMBER KIND DATE
---------- ------ --------
PATENT INFORMATION: US 2005181977 A1 20050818 <--
APPLICATION INFO.: US 2004-986231 A1 20041110 (10)

NUMBER DATE
---------- --------
PRIORITY INFORMATION: US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 182
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 56396
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 13 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:208533 USPATFULL <<LOGINID::20080212>>
TITLE: Medical implants and anti-scarring agents
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005181011	A1	20050818 <--
APPLICATION INFO.:	US 2004-1792	A1	20041202 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER DATE

PRIORITY INFORMATION: US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 177
EXEMPLARY CLAIM: 1-4994
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 56421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 14 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:208530 USPATFULL <<LOGINID::20080212>>
TITLE: Medical implants and anti-scarring agents
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005181008	A1	20050818 <--
APPLICATION INFO.:	US 2004-1786	A1	20041202 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-518785P	20031110 (60)
	US 2003-523908P	20031120 (60)
	US 2003-524023P	20031120 (60)
	US 2003-525226P	20031124 (60)
	US 2003-526541P	20031203 (60)
	US 2004-586861P	20040709 (60)
	US 2004-578471P	20040609 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 178
EXEMPLARY CLAIM: 1-4736
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 56377
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 15 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:205930 USPATFULL <<LOGINID::20080212>>
TITLE: Polymer compositions and methods for their use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

NUMBER	KIND	DATE
PATENT INFORMATION: US 2005178396	A1	20050818 <--
APPLICATION INFO.: US 2004-6905	A1	20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER	DATE
PRIORITY INFORMATION: US 2004-611077P	20040917 (60)
US 2004-586861P	20040709 (60)
US 2004-566569P	20040428 (60)
US 2003-526541P	20031203 (60)
US 2003-525226P	20031124 (60)
US 2003-523908P	20031120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1-8063
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 33965
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 16 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:205929 USPATFULL <<LOGINID::20080212>>
TITLE: Polymer compositions and methods for their use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

NUMBER	KIND	DATE
PATENT INFORMATION: US 2005178395	A1	20050818 <--
APPLICATION INFO.: US 2004-6900	A1	20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER	DATE
PRIORITY INFORMATION: US 2004-611077P	20040917 (60)
US 2004-586861P	20040709 (60)
US 2004-566569P	20040428 (60)
US 2003-526541P	20031203 (60)
US 2003-525226P	20031124 (60)
US 2003-523908P	20031120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1-7302
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 34043
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 17 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:203799 USPATFULL <<LOGINID::20080212>>
TITLE: Medical implants and anti-scarring agents
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND, CH (non-U.S. corporation)

NUMBER	KIND	DATE
PATENT INFORMATION: US 2005177225	A1	20050811 <--
APPLICATION INFO.: US 2004-6895	A1	20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

NUMBER	DATE
PRIORITY INFORMATION: US 2004-586861P	20040709 (60)
US 2004-578471P	20040609 (60)
US 2003-526541P	20031203 (60)
US 2003-525226P	20031124 (60)
US 2003-523908P	20031120 (60)
US 2003-524023P	20031120 (60)
US 2003-518785P	20031110 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 173
EXEMPLARY CLAIM: 1-11788
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 56371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 18 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:202285 USPATFULL <<LOGINID::20080212>>
TITLE: Polymer compositions and methods for their use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005175703	A1	20050811 <--
APPLICATION INFO.:	US 2004-6888	A1	20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-611077P	20040917 (60)
	US 2004-586861P	20040709 (60)
	US 2004-566569P	20040428 (60)
	US 2003-526541P	20031203 (60)
	US 2003-525226P	20031124 (60)
	US 2003-523908P	20031120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1-7576
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 33992
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and

the prevention of cartilage loss.

L8 ANSWER 19 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:202247 USPATFULL <<LOGINID::20080212>>
TITLE: Polymer compositions and methods for their use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005175665	A1	20050811 <--
APPLICATION INFO.:	US 2004-6896	A1	20041207 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-611077P	20040917 (60)
	US 2004-586861P	20040709 (60)
	US 2004-566569P	20040428 (60)
	US 2003-526541P	20031203 (60)
	US 2003-525226P	20031124 (60)
	US 2003-523908P	20031120 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1-7822
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 33978
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis,

treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L8 ANSWER 20 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:202245 USPATFULL <<LOGINID::20080212>>
TITLE: Medical implants and anti-scarring agents
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005175663	A1	20050811	<--
APPLICATION INFO.:	US 2004-1791	A1	20041202 (11)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-518785P	20031110 (60)
	US 2003-523908P	20031120 (60)
	US 2003-524023P	20031120 (60)
	US 2003-525226P	20031124 (60)
	US 2003-526541P	20031203 (60)
	US 2004-586861P	20040709 (60)
	US 2004-578471P	20040609 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 180
EXEMPLARY CLAIM: 1-3944
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 56451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a

second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 21 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:190568 USPATFULL <<LOGINID::20080212>>
TITLE: Medical implants and anti-scarring agents
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWEDEN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005165488	A1	20050728	<--
APPLICATION INFO.:	US 2004-6912	A1	20041207 (11)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-586861P	20040709 (60)
	US 2004-578471P	20040609 (60)
	US 2003-526541P	20031203 (60)
	US 2003-525226P	20031124 (60)
	US 2003-523908P	20031120 (60)
	US 2003-524023P	20031120 (60)
	US 2003-518785P	20031110 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 176
EXEMPLARY CLAIM: 1-3153
NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56407
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 22 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:184075 USPATFULL <<LOGINID::20080212>>
TITLE: Histone deacetylase inhibitors
INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES
Cao, Sheldon X., San Diego, CA, UNITED STATES
Gangloff, Anthony R., San Diego, CA, UNITED STATES
Jennings, Andrew J., La Jolla, CA, UNITED STATES
Stafford, Jeffrey A., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005159470	A1	20050721	<--
APPLICATION INFO.:	US 2004-13056	A1	20041214 (11)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-531567P	20031219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SYRRX, INC., 10410 SCIENCE CENTER DRIVE, SAN DIEGO, CA,
92121, US
NUMBER OF CLAIMS: 70
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 4483
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Histone deacetylase inhibitors and uses thereof are provided that have the general Z-Q-L-M

wherein Z is a 5-membered aromatic heterocycle as shown herein, each X is independently selected from the group consisting of CR.sub.5 and N; each Y is independently selected from the group consisting of O, S and NR.sub.5; R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein; Q is a substituted or unsubstituted aromatic ring; M is a substituent capable of complexing with a protein metal ion; and L is a substituent comprising a chain of 1-10 atoms connecting the M substituent to the Q substituent.

L8 ANSWER 23 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:172409 USPATFULL <<LOGINID::20080212>>
TITLE: Medical implants and anti-scarring agents
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005149158	A1	20050707	<--
APPLICATION INFO.:	US 2004-409	A1	20041129 (11)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-518785P	20031110 (60)
	US 2003-523908P	20031120 (60)
	US 2003-524023P	20031120 (60)
	US 2003-525226P	20031124 (60)
	US 2003-526541P	20031203 (60)
	US 2004-586861P	20040709 (60)
	US 2004-578471P	20040609 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 178
EXEMPLARY CLAIM: 1-274
NUMBER OF DRAWINGS: 28 Drawing Page(s)

LINE COUNT: 56404
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 24 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:172331 USPATFULL <<LOGINID::20080212>>
TITLE: Medical implants and anti-scarring agents
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PATENT ASSIGNEE(S): Angiotech International AG, Zug, SWITZERLAND (non-U.S.
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005149080	A1	20050707	<--
APPLICATION INFO.:	US 2004-1418	A1	20041130 (11)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-586861P	20040709 (60)
	US 2004-578471P	20040609 (60)
	US 2003-526541P	20031203 (60)
	US 2003-525226P	20031124 (60)
	US 2003-523908P	20031120 (60)
	US 2003-524023P	20031120 (60)
	US 2003-518785P	20031110 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 178
EXEMPLARY CLAIM: 1-806
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 56418
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L8 ANSWER 25 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:164658 USPATFULL <<LOGINID::20080212>>
TITLE: Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least on matrix metalloproteinase inhibitor
INVENTOR(S): Breton, Lionel, Versailles, FRANCE
Mahe, Yann, Morsang sur Orge, FRANCE
PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005142081	A1	20050630 <--
APPLICATION INFO.:	US 2005-65356	A1	20050225 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-179934, filed on 26 Jun 2002, GRANTED, Pat. No. US 6884425

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2001-8433	20010626

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940

DUKE STREET, ALEXANDRIA, VA, 22314, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1-16
LINE COUNT: 1196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A cosmetic or dermatological composition characterized in that it comprises an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one metalloproteinase inhibiting compound.

L8 ANSWER 26 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:159024 USPATFULL <<LOGINID::20080212>>
TITLE: Histone deacetylase inhibitors
INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES
Gangloff, Anthony R., San Diego, CA, UNITED STATES
Jennings, Andrew J., La Jolla, CA, UNITED STATES
PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005137234	A1	20050623	<--
APPLICATION INFO.:	US 2004-13234	A1	20041214 (11)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-531371P	20031219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SYRRX, INC., 10410 SCIENCE CENTER DRIVE, SAN DIEGO, CA,
92121, US
NUMBER OF CLAIMS: 98
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 4764
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Histone deacetylase inhibitors and uses thereof are provided that have the general formula: Z-L-M wherein Z, L and M are as defined herein.

L8 ANSWER 27 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:159022 USPATFULL <<LOGINID::20080212>>
TITLE: Histone deacetylase inhibitors
INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES
Brown, Jason W., San Diego, CA, UNITED STATES
Cao, Sheldon X., San Diego, CA, UNITED STATES
Gangloff, Anthony R., San Diego, CA, UNITED STATES

Jennings, Andrew J., La Jolla, CA, UNITED STATES
Stafford, Jeffrey A., San Diego, CA, UNITED STATES
Vu, Phong H., San Diego, CA, UNITED STATES
Xiao, Xiao-Yi, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005137232	A1	20050623	<--
APPLICATION INFO.:	US 2004-803580	A1	20040317 (10)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-455437P	20030317 (60)
	US 2003-531203P	20031219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SYRRX, INC., 10410 SCIENCE CENTER DRIVE, SAN DIEGO, CA,
92121, US
NUMBER OF CLAIMS: 144
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 4750
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds that may be used to inhibit histone deacetylase having the formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

L8 ANSWER 28 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:118290 USPATFULL <<LOGINID::20080212>>
TITLE: Method and compositions for the treatment and prevention of pain and inflammation
INVENTOR(S): Pulaski, Steven P., Simi Valley, CA, UNITED STATES
Kundel, Susan, Basel, SWITZERLAND
PATENT ASSIGNEE(S): Pharmacia Corporation, Chesterfield, MO, UNITED STATES
(U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005101563	A1	20050512	<--
APPLICATION INFO.:	US 2004-783160	A1	20040219 (10)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-215539, filed on 9 Aug 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-312211P	20010814 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HARNESS, DICKEY & PIERCE, P.L.C., 7700 BONHOMME, SUITE 400, ST LOUIS, MO, 63105, US
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 4596
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of preventing or treating pain or inflammation in a subject is provided by administering to the subject a Cox-2 inhibitor and a polyunsaturated fatty acid, or a prodrug thereof, wherein the amount of a Cox-2 inhibitor and polyunsaturated fatty acid or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount. Glucosamine and/or chondroitin can optionally be present. Therapeutic compositions that contain the combination of Cox-2 inhibitor and polyunsaturated fatty acid and, optionally, the glucosamine and/or chondroitin, are disclosed, as are pharmaceutical compositions.

L8 ANSWER 29 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:112275 USPATFULL <<LOGINID::20080212>>
TITLE: Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases
INVENTOR(S): Salter-Cid, Luisa Maria, San Diego, CA, UNITED STATES
Wang, Eric Yanjun, San Diego, CA, UNITED STATES
Cockerill, Keith, San Diego, CA, UNITED STATES
Linnik, Matthew D., Solana Beach, CA, UNITED STATES
Victoria, Edward J., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005096360	A1	20050505	<--
APPLICATION INFO.:	US 2004-913253	A1	20040806 (10)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-493835P	20030808 (60)
	US 2003-502401P	20030912 (60)

US 2004-568999P 20040506 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO,
CA, 94304-1018, US
NUMBER OF CLAIMS: 65
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 3282
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylhydrazine compounds, hydroxylamine (aminooxy) compounds, and other compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several disorders, including multiple sclerosis.

L8 ANSWER 30 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2005:68473 USPATFULL <<LOGINID::20080212>>
TITLE: Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight
INVENTOR(S): Fagot, Dominique, Paris, FRANCE
Bernerd, Francoise, Paris, FRANCE
PATENT ASSIGNEE(S): L'OREAL, PARIS, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005058611	A1	20050317 <--
APPLICATION INFO.:	US 2004-922929	A1	20040823 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2003-10103	20030822
	US 2003-530233P	20031218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX
1404, ALEXANDRIA, VA, 22313-1404
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)

LINE COUNT: 1427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Cosmetic/dermatological compositions useful for preventing and/or combating the degradation of collagen fibers induced by solar radiation typically characterized by a UV-A/UV-B ratio ranging from 10 and 17, advantageously formulated for topical application onto the skin and/or scalp, contain a thus effective amount of at least one inhibitor of the production of photoinduced keratinocytic cytosoluble factors, notably sodium butyrate.

L8 ANSWER 31 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2004:335675 USPATFULL <<LOGINID::20080212>>
TITLE: Histone deacetylase inhibitors
INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES
Brown, Jason W., San Diego, CA, UNITED STATES
Cao, Sheldon X., San Diego, CA, UNITED STATES
Gangloff, Anthony R., San Diego, CA, UNITED STATES
Jennings, Andrew J., La Jolla, CA, UNITED STATES
Stafford, Jeffrey A., San Diego, CA, UNITED STATES
Vu, Phong H., San Diego, CA, UNITED STATES
Xiao, Xiao-Yi, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004266769	A1	20041230	<--
	US 7169801	B2	20070130	
APPLICATION INFO.:	US 2004-803344	A1	20040317 (10)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-455437P	20030317 (60)
	US 2003-531203P	20031219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SYRRX, INC., 10410 SCIENCE CENTER DRIVE, SAN DIEGO, CA,
92121
NUMBER OF CLAIMS: 67
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 5381
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds that may be used to inhibit histone deacetylase having the formula

Z-Q-L-M or Z-L-M

wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

L8 ANSWER 32 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2004:321565 USPATFULL <<LOGINID::20080212>>
TITLE: Histone deacetylase inhibitors
INVENTOR(S): Bressi, Jerome C., San Diego, CA, UNITED STATES
Brown, Jason W., San Diego, CA, UNITED STATES
Cao, Sheldon X., San Diego, CA, UNITED STATES
Gangloff, Anthony R., San Diego, CA, UNITED STATES
Jennings, Andrew J., La Jolla, CA, UNITED STATES
Stafford, Jeffrey A., San Diego, CA, UNITED STATES
Vu, Phong H., San Diego, CA, UNITED STATES
Xiao, Xiao-Yi, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Syrrx, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004254220	A1	20041216	<--
APPLICATION INFO.:	US 2004-803575	A1	20040317 (10)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-455437P	20030317 (60)
	US 2003-531203P	20031219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JOHN P. WOOLDRIDGE, 252 KAIPII PL, KIHEI, HI 96753, HI,
96753
NUMBER OF CLAIMS: 95
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 4834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds that may be used to inhibit histone deacetylase having the formula

Z-Q-L-M or Z-L-M

wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between

0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.

L8 ANSWER 33 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2004:280854 USPATFULL <<LOGINID::20080212>>
TITLE: Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
INVENTOR(S): Seibert, Karen, St. Louis, MO, UNITED STATES
PATENT ASSIGNEE(S): Pharmacia Corporation, Chesterfield, MO (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004220155	A1	20041104 <--
APPLICATION INFO.:	US 2004-803145	A1	20040317 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-458595P	20030328 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Charles E. Dunlap, P.O. Box 11070, Columbia, SC, 29211-1070
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 5421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method is described for providing a steroid-sparing benefit to a subject that is in need of, or that is presently receiving, a corticosteroid, the method comprising administering to the subject a cyclooxygenase-2 inhibitor in combination with a corticosteroid. Therapeutic compositions, pharmaceutical compositions and kits that are useful for implementing the present method are also described.

L8 ANSWER 34 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2004:145285 USPATFULL <<LOGINID::20080212>>
TITLE: Antiangiogenic drug to treat cancer, arthritis and retinopathy
INVENTOR(S): Kawai, Megumi, Libertyville, IL, UNITED STATES
Henkin, Jack, Highland Park, IL, UNITED STATES
Sheppard, George S., Wilmette, IL, UNITED STATES
Craig, Richard A., Racine, WI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004110959	A1	20040610 <--

US 6849757 B2 20050201
APPLICATION INFO.: US 2003-616628 A1 20030710 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 1999-316856, filed on 21 May 1999, GRANTED, Pat. No. US 6632961

NUMBER	DATE

PRIORITY INFORMATION: US 1998-86491P 19980522 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 2033
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having Formula I ##STR1##

or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting angiogenesis in a mammal.

L8 ANSWER 35 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2004:145266 USPATFULL <<LOGINID::20080212>>
TITLE: Complementary DNAs encoding proteins with signal peptides
INVENTOR(S): Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
Clusel, Catherine, Vincennes, FRANCE
Duclert, Aymeric, Saint-Maur, FRANCE
PATENT ASSIGNEE(S): GENSET, S.A., Paris, FRANCE (non-U.S. corporation)

NUMBER	KIND	DATE	
PATENT INFORMATION: US 2004110939	A1	20040610	<--
US 2006009633	A9	20060112	

APPLICATION INFO.: US 2001-978360 A1 20011015 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-663600, filed on 15 Sep 2000, GRANTED, Pat. No. US 6573068

NUMBER	DATE

PRIORITY INFORMATION: WO 1998-IB2122 19981217
WO 1999-IB282 19990209
WO 2000-IB951 20000621
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL
ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1,
GAINESVILLE, FL, 326066669
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 11396
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The sequences of cDNAs encoding secreted proteins are disclosed. The cDNAs can be used to express secreted proteins or fragments thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNAs may also be used to design expression vectors and secretion vectors.

L8 ANSWER 36 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2004:38339 USPATFULL <<LOGINID::20080212>>
TITLE: Method of making a product with a micro or nano sized structure and product
INVENTOR(S): Van Rijn, Cornelis Johannes Maria, Hengelo, NETHERLANDS
Vogelaar, Laura, Enschede, NETHERLANDS
Nijdam, Wietze, Enschede, NETHERLANDS
Barsema, Jonathan Nathaniel, Enschede, NETHERLANDS
Wessling, Matthias, Enschede, NETHERLANDS

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004028875	A1	20040212 <--
APPLICATION INFO.:	US 2003-433275	A1	20030929 (10)
	WO 2001-NL874		20011203

	NUMBER	DATE
PRIORITY INFORMATION:	NL 2000-1016779	20001202

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: YOUNG & THOMPSON, 745 SOUTH 23RD STREET 2ND FLOOR,
ARLINGTON, VA, 22202
NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 2524
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Using phase separation technique perforated as well as non-perforated polymeric structures can be made with high aspect ratios (>5). By varying the phase separation process the properties (e.g. porous, non-porous, dense, open skin) of the moulded product can be tuned. Applications are described in the field of micro fluidics (e.g. micro arrays, electrophoretic boards), optics, polymeric solar cells, ball grid arrays, and tissue engineering.

L8 ANSWER 37 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2003:334723 USPATFULL <<LOGINID::20080212>>
TITLE: Composition containing a sapogenin and use thereof
INVENTOR(S): Besne, Isabelle, Paris, FRANCE
PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003235599	A1	20031225	<--
APPLICATION INFO.:	US 2003-393913	A1	20030324 (10)	

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2002-4611	20020412
	US 2002-374157P	20020422 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940
DUKE STREET, ALEXANDRIA, VA, 22314
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 782
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a composition containing a sapogenin, and/or a sapogenin ester, and to the use of a sapogenin and/or a sapogenin ester to manufacture a composition that is suitable for topical application to the skin, and in a method wherein sapogenin and/or a sapogenin ester are used as agents for the of smoothing out wrinkles and fine lines, in particular expression wrinkles and fine lines. The sapogenin may be used/provided in the form of a natural extract containing it. A preferred sapogenin is diosgenin.

L8 ANSWER 38 OF 50 USPATFULL on STN

ACCESSION NUMBER: 2003:273494 USPATFULL <<LOGINID::20080212>>
TITLE: Antiangiogenic drug to treat cancer, arthritis and retinopathy
INVENTOR(S): Kawai, Megumi, Libertyville, IL, United States
Henkin, Jack, Highland Park, IL, United States
Sheppard, George S., Wilmette, IL, United States
Craig, Richard A., Racine, WI, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6632961	B1	20031014 <--
APPLICATION INFO.:	US 1999-316856		19990521 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-86491P	19980522 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Lukton, David
LEGAL REPRESENTATIVE: Steele, Gregory W., Donner, B. Gregory
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having Formula I ##STR1##

or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting angiogenesis in a mammal.

L8 ANSWER 39 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2003:200520 USPATFULL <<LOGINID::20080212>>
TITLE: Intradermal-penetration agents for topical local anesthetic administration
INVENTOR(S): Fischer, Wilfried, Neubiberg, GERMANY, FEDERAL REPUBLIC
OF
Huber, Petra, Muenchen, GERMANY, FEDERAL REPUBLIC OF
Mason, Paul, Flemington, NJ, UNITED STATES
PATENT ASSIGNEE(S): EpiCept Corp. (non-U.S. corporation)

NUMBER KIND DATE
--- --- ---
PATENT INFORMATION: US 2003138505 A1 20030724 <--
US 6746689 B2 20040608
APPLICATION INFO.: US 2002-201901 A1 20020725 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-523652, filed on 10 Mar 2000, GRANTED, Pat. No. US 6455066
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000,
WASHINGTON, DC, 20006
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 897
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A non-invasive and non-systemic method for administering a local anesthetic. The method comprises topical application of a local anesthetic in combination with an intradermal-penetration agent selected from the group consisting an aloe composition, a triglyceride, and a mixture thereof.

L8 ANSWER 40 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2003:141014 USPATFULL <<LOGINID::20080212>>
TITLE: Cell proliferation inhibitors
INVENTOR(S): Li, Qun, Libertyville, IL, UNITED STATES
Sham, Hing, Mundelein, IL, UNITED STATES
Woods, Keith W., Libertyville, IL, UNITED STATES
Steiner, Beth A., Remington, IN, UNITED STATES
Gwaltney, Stephen L., II, Lindenhurst, IL, UNITED STATES
Barr, Kenneth J., San Francisco, CA, UNITED STATES
Imade, Hovis M., Chicago, IL, UNITED STATES
Rosenberg, Saul, Grayslake, IL, UNITED STATES

NUMBER KIND DATE
--- --- ---
PATENT INFORMATION: US 2003096856 A1 20030522 <--
US 6924304 B2 20050802
APPLICATION INFO.: US 2002-301427 A1 20021121 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 2000-579705, filed on 26 May 2000, GRANTED, Pat. No. US 6521658

NUMBER DATE
--- ---

PRIORITY INFORMATION: US 1999-136542P 19990528 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT
PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 3231
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having formula (I) ##STR1##

inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

L8 ANSWER 41 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2003:105821 USPATFULL <<LOGINID::20080212>>
TITLE: Cosmetic or dermatological composition comprising an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one anti-inflammatory compound
INVENTOR(S): Breton, Lionel, Versailles, FRANCE
Mahe, Yann, Morsang sur Orge, FRANCE
PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003072732	A1	20030417	<--
	US 6998129	B2	20060214	
APPLICATION INFO.:	US 2002-179955	A1	20020626 (10)	

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2001-8434	20010626

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH
FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1099
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A cosmetic or dermatological composition characterized In that it

comprises an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one anti-inflammatory compound.

L8 ANSWER 42 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2003:64318 USPATFULL <<LOGINID::20080212>>
TITLE: Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor
INVENTOR(S): Breton, Lionel, Versailles, FRANCE
Mahe, Yann, Morsang sur Orge, FRANCE
PATENT ASSIGNEE(S): L'OREAL, Paris, FRANCE, 75008 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003044438	A1	20030306	<--
	US 6884425	B2	20050426	
APPLICATION INFO.:	US 2002-179934	A1	20020626 (10)	

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2001-8433	20010626

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 1199
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A cosmetic or dermatological composition characterized in that it comprises an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one metalloproteinase inhibiting compound.

L8 ANSWER 43 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2003:57103 USPATFULL <<LOGINID::20080212>>
TITLE: Anti-fungal composition
INVENTOR(S): Jira, Vic, El Monte, CA, UNITED STATES
Jirathitikal, Vichai, Chachoengsao, THAILAND

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003039667	A1	20030227	<--

APPLICATION INFO.: US 2002-228280 A1 20020827 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2001-314666P 20010827 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BLANK ROME COMISKY & MCCAULEY, LLP, 900 17TH STREET,
N.W., SUITE 1000, WASHINGTON, DC, 20006
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1664
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A multivalent fungal vaccine comprising one or more heat-inactivated fungal antigens, wherein at least one fungal antigen is effective in producing an immune response in a host when said vaccine is administered orally at a dose that is sufficient for preventing or treating the fungal disease in said host. Also described are methods for making and using an orally available anti-fungal vaccine.

L8 ANSWER 44 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2003:47790 USPATFULL <<LOGINID::20080212>>
TITLE: Cell proliferation inhibitors
INVENTOR(S): Li, Qun, Libertyville, IL, United States
Sham, Hing, Mundelein, IL, United States
Woods, Keith W., Libertyville, IL, United States
Steiner, Beth A., Remington, IN, United States
Gwaltney, II, Stephen L., Lindenhurst, IL, United States
Barr, Kenneth J., San Francisco, CA, United States
Imade, Hovis M., Chicago, IL, United States
Rosenberg, Saul, Grayslake, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6521658 B1 20030218 <--
APPLICATION INFO.: US 2000-579705 20000526 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-136542, filed on 28 May 1999
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McKane, Joseph K.
ASSISTANT EXAMINER: Small, Andrea D.

LEGAL REPRESENTATIVE: Donner, B. Gregory
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having formula (I) ##STR1##

inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

L8 ANSWER 45 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2002:246388 USPATFULL <<LOGINID::20080212>>
TITLE: Intradermal-penetration agents for topical local anesthetic administration
INVENTOR(S): Fischer, Wilfried, Neubiberg, GERMANY, FEDERAL REPUBLIC OF
Stoeger, Katharina, Schrobenhausen, GERMANY, FEDERAL REPUBLIC OF
Huber, Petra, Munich, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Epicept Corporation, Englewood Cliffs, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6455066	B1	20020924	<--
APPLICATION INFO.:	US 2000-523652		20000310 (9)	

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Lankford, Jr., Leon B.
ASSISTANT EXAMINER: Coe, Susan D.
LEGAL REPRESENTATIVE: Pennie & Edmonds, LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 791
AB A non-invasive and non-systemic method for administering a local anesthetic. The method comprises topical application of a local anesthetic in combination with an intradermal-penetration agent selected from the group consisting an aloe composition, a triglyceride, and a mixture thereof.

L8 ANSWER 46 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2002:32704 USPATFULL <<LOGINID::20080212>>

TITLE: Substituted phenyl farnesyltransferase inhibitors
INVENTOR(S): Wang, Wei-Bo, Grayslake, IL, UNITED STATES
Curtin, Michael L., Pleasant Prairie, WI, UNITED STATES
Fakhoury, Stephen A., Ann Arbor, MI, UNITED STATES
Gwaltney, Stephen L., II, Lindenhurst, IL, UNITED STATES
Hasvold, Lisa A., Grayslake, IL, UNITED STATES
Hutchins, Charles W., Green Oaks, IL, UNITED STATES
Li, Qun, Libertyville, IL, UNITED STATES
Lin, Nan-Horng, Vernon Hills, IL, UNITED STATES
Nelson, Lissa Taka Jennings, Highland Park, IL, UNITED STATES
O'Connor, Steve, Guilford, CT, UNITED STATES
Sham, Hing L., Vernon Hills, IL, UNITED STATES
Sullivan, Gerard M., Round Lake Beach, IL, UNITED STATES
Wang, Gary T., Niles, IL, UNITED STATES
Wang, Xilu, Skokie, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019527	A1	20020214 <--
APPLICATION INFO.:	US 2001-842391	A1	20010425 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-200165P	20000427 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gregory W. Steele, Abbott Laboratories, AP6D/2 D-377,
100 Abbott Park Road, Abbott Park, IL, 60064-6050
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
LINE COUNT: 9159
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) ##STR1##

or pharmaceutically acceptable salts thereof, inhibit farnesyltransferase. Methods for making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

L8 ANSWER 47 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2002:5985 USPATFULL <<LOGINID::20080212>>
TITLE: Anti-inflammatory compositions comprising peptide

derivatives of a-MSH/algal extracts
INVENTOR(S): Mahe, Yann, Morsang sur Orge, FRANCE
Billoni, Nelly, Valmondois, FRANCE
Breton, Lionel, Versailles, FRANCE
Bui-Bertrand, Lien, Savigny sur Orge, FRANCE
PATENT ASSIGNEE(S): Societe L'Oreal S.A., Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6337315	B1	20020108 <--
APPLICATION INFO.:	US 1999-353650		19990715 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1998-9055	19980715

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Robinson, Hope A.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Anti-inflammatory compositions, well suited for a wide variety of therapeutic/cosmetic applications, comprise combinatory immixture of (1) an effective anti-inflammatory amount of at least one peptide derivative of a-type melanocyte stimulating hormone (a-MSH), or functional biological equivalent thereof, and (2) an effective anti-inflammatory response-enhancing amount of at least one marine algal extract.

L8 ANSWER 48 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2001:215075 USPATFULL <<LOGINID::20080212>>
TITLE: 3-substituted indole angiogenesis inhibitors
INVENTOR(S): BaMaung, Nwe Y., Niles, IL, United States
Craig, Richard A., Racine, WI, United States
Kawai, Megumi, Libertyville, IL, United States
Wang, Jieyi, Gurnee, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6323228 B1 20011127 <--
APPLICATION INFO.: US 2000-663005 20000915 (9)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McKane, Joseph K.
ASSISTANT EXAMINER: D'Souza, Andrea M
LEGAL REPRESENTATIVE: Donner, B. Gregory, Steele, Gregory
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 1832
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 3-Substituted indole carbohydrazides having the formula ##STR1##

are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.

L8 ANSWER 49 OF 50 USPATFULL on STN
ACCESSION NUMBER: 2001:67679 USPATFULL <<LOGINID::20080212>>
TITLE: Oxazoline antiproliferative agents
INVENTOR(S): Gwaltney, II, Stephen L., Lindenhurst, IL, United States
Jae, Hwan-Soo, Glencoe, IL, United States
Kalvin, Douglas M., Buffalo Grove, IL, United States
Liu, Gang, Gurnee, IL, United States
Sham, Hing L., Mundelein, IL, United States
Li, Qun, Libertyville, IL, United States
Claiborne, Akiyo K., Mundelein, IL, United States
Wang, Le, Mundelein, IL, United States
Barr, Kenneth J., San Francisco, CA, United States
Woods, Keith W., Libertyville, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

NUMBER	KIND	DATE
PATENT INFORMATION: US 6228868	B1	20010508 <--
APPLICATION INFO.: US 1999-360463		19990723 (9)

NUMBER	DATE
PRIORITY INFORMATION: US 1998-94241P	19980727 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huang, Evelyn Mei
LEGAL REPRESENTATIVE: Steele, Gregory W., Donner, B. Gregory

NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 3207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having Formula I ##STR1##

are useful for treating cancer. Also disclosed are pharmaceutical compositions comprising compounds of Formula I, and methods of treating cancer in a mammal.

L8 ANSWER 50 OF 50 USPATFULL on STN
ACCESSION NUMBER: 87:85826 USPATFULL <<LOGINID::20080212>>
TITLE: Artificially vascularized graft
INVENTOR(S): Viggiano, Donato A., 1090 Virginia Ave., Ft. Pierce, FL, United States 33450

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4713055		19871215	<--
APPLICATION INFO.:	US 1986-842351		19860318	(6)

RELATED APPLN. INFO.: Division of Ser. No. US 1983-506858, filed on 22 Jun 1983, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rosenbaum, C. Fred
ASSISTANT EXAMINER: Kartchner, Gene B.
LEGAL REPRESENTATIVE: Malin, Eugene F.
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 697
AB Apparatus and method for temporarily keeping alive animal flaps or grafts by perfusing artificial blood initially through a tubular semi-permeable membrance including a plurality of capillaries and thereafter perfusing the artificial blood into the flaps or grafts.

=> d his

(FILE 'HOME' ENTERED AT 13:13:20 ON 12 FEB 2008)

FILE 'REGISTRY' ENTERED AT 13:13:40 ON 12 FEB 2008
E PERFLUOROCARBON
L1 26 S E1-E12

FILE 'CAPLUS, BIOSIS, MEDLINE, USPATFULL, EMBASE' ENTERED AT 13:14:28 ON
12 FEB 2008
L2 143119 S L1 OR (PERFLUOR?)
L3 25249 S L2 AND (EMULSION?)
L4 3019 S L3 AND (NERV? OR ENDOCRIN?)
L5 820 S L4 AND (CAPILLAR?)
L6 70 S L5 AND (SKIN(P)CAPILLAR?)
L7 70 DUP REM L6 (0 DUPLICATES REMOVED)
L8 50 S L7 AND (PY<=2005)

=> fil stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	130.87	193.34

FILE 'STNGUIDE' ENTERED AT 13:18:47 ON 12 FEB 2008

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 8, 2008 (20080208/UP).

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	193.82

FILE 'CAPLUS' ENTERED AT 13:23:48 ON 12 FEB 2008

FILE COVERS 1907 - 12 Feb 2008 VOL 148 ISS 7
FILE LAST UPDATED: 11 Feb 2008 (20080211/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 13:13:20 ON 12 FEB 2008)

FILE 'REGISTRY' ENTERED AT 13:13:40 ON 12 FEB 2008
E PERFLUOROCARBON
L1 26 S E1-E12

FILE 'CAPLUS, BIOSIS, MEDLINE, USPATFULL, EMBASE' ENTERED AT 13:14:28 ON
12 FEB 2008
L2 143119 S L1 OR (PERFLUOR?)
L3 25249 S L2 AND (EMULSION?)
L4 3019 S L3 AND (NERV? OR ENDOCRIN?)
L5 820 S L4 AND (CAPILLAR?)
L6 70 S L5 AND (SKIN(P)CAPILLAR?)
L7 70 DUP REM L6 (0 DUPLICATES REMOVED)
L8 50 S L7 AND (PY<=2005)

FILE 'STNGUIDE' ENTERED AT 13:18:47 ON 12 FEB 2008

FILE 'CAPLUS' ENTERED AT 13:23:48 ON 12 FEB 2008

=> s l8 and perfluoro?
56097 PERFLUORO?
L9 0 L8 AND PERFLUORO?

=> s perfluor?
L10 59156 PERFLUOR?

=> s l10 and emulsion?
255416 EMULSION?
L11 3000 L10 AND EMULSION?

=> s l11 and (skin? or epiderm?)
285149 SKIN?
88566 EPIDERM?
L12 125 L11 AND (SKIN? OR EPIDERM?)

=> s l12 and (capilar?)

```
          19 CAPILAR?
L13         0 L12 AND (CAPILAR?)

=> s l12 and blood?
      1367344 BLOOD?
L14         14 L12 AND BLOOD?

=> dup rem 14
ENTER L# LIST OR (END):l14
'14' IS NOT VALID.  VALID FILE NAMES ARE 'CAPLUS'
You have entered a file name of duplicates to keep that is not
referenced by any of the L#s specified for this DUPLICATE command.
The file names of duplicates that can be kept are listed above.
Please enter one of these file names.

=> dup rem l14
PROCESSING COMPLETED FOR L14
L15         14 DUP REM L14 (0 DUPLICATES REMOVED)

=> d ibib ab 1-
YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y

L15  ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:       2007:999474  CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER:        147:330635
TITLE:                  Cell labeling with perfluorocarbon nanoparticles for
                        magnetic resonance imaging and spectroscopy
INVENTOR(S):            Wickline, Samuel A.; Lanza, Gregory M.
PATENT ASSIGNEE(S):     Washington University, USA
SOURCE:                 PCT Int. Appl., 84pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:          Patent
LANGUAGE:               English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

   PATENT NO.         KIND   DATE       APPLICATION NO.       DATE
   ---------------    ----   --------   --------------------  --------
   WO 2007100715       A2    20070907   WO 2007-US4823        20070223
   WO 2007100715       A3    20080110
      W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
          CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
          GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
          KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
          MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
          RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
```

TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: US 2006-776743P P 20060224
AB Methods of obtaining cells internally labeled with perfluorocarbon nanoparticles suitable for magnetic resonance imaging and spectroscopy are disclosed. Also disclosed are methods for obtaining magnetic resonance imaging data from labeled cells under clin. relevant scan times and field strengths. Finally, the application further discloses methods of specifically detecting and distinguishing magnetic resonance imaging and spectroscopy data from two distinct sets of cells labeled with distinct types of perfluorocarbon nanoparticles.

L15 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1271365 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 147:508703
TITLE: Methods for assessing cell labeling
INVENTOR(S): Ahrens, Eric T.; Kornblith, Paul
PATENT ASSIGNEE(S): Celsense Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 16pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007258886	A1	20071108	US 2007-787520	20070416

PRIORITY APPLN. INFO.: US 2006-792242P P 20060414
AB The disclosure relates to methods for labeling cells ex vivo with imaging agents that can be detected by MRI or PET techniques, or other techniques that permit non-invasive imaging of living organisms. The labeled cells can be re-administered to the patient and the movements of the labeled cells can be tracked in vivo by MRI, PET or other techniques. In part, the disclosed methods involve labeling a series of cell samples ex vivo determining the association of label with the cells, such that an appropriate dosage of labeled cells can be determined for each patient. Thus, a linear perfluoropolyether (PFPE) mol. was conjugated to com. available dyes, such as Bodipy-TR dye and Alexa 647. Emulsions were made using blended mixts. of the PFPE-dye conjugate and the nonconjugated PFPE. It is expected that the materials would show a small particle size of comparable size as the nonfluorescent versions, the fluorescent properties would be

maintained, the materials would show a dose dependent fluorescence intensity, the fluorescent spectrum would be unaffected by the conjugation to the PFPE, and labeled cells would exhibit similar cell loading characteristics as the nonfluorescent equivalent It is also expected that cells labeled with the dual mode agent would show a linear correlation with 19F NMR-measured uptake.

L15 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:498341 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 143:13425
TITLE: Preparation for treating neurogenic and endocrine disorders of microcirculation
INVENTOR(S): Klyushnik, T. P.; Lushnikov, K. V.; Chemeris, N. K.; Tikhonova, I. V.; Tankanag, A. V.; Shibaev, N. V.; Korneeva, R. V.
PATENT ASSIGNEE(S): Otkrytoe Aktsionernoe Obshchestvo "Faberlik", Russia
SOURCE: Russ., No pp. given
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2253440	C1	20050610	RU 2004-109556	20040331
WO 2005094778	A1	20051013	WO 2005-RU132	20050323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1744726	A1	20070124	EP 2005-731686	20050323
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2007275097	A1	20071129	US 2007-594171	20070718

PRIORITY APPLN. INFO.: RU 2004-109556 A 20040331
WO 2005-RU132 W 20050323

AB The present innovation deals with applying prepns. affecting the values of blood microcirculation in skin. The suggested preparation is the

emulsion of perfluorocarbons that increases skin resistance to neg. impacts and favorably affects microcirculation by steadily increasing its total level that enables to improve the state of microcirculatory canal of skin.

L15 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:270036 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 140:281418
TITLE: Control of nitric oxide bioactivity by perfluorocarbons, and therapeutic use
INVENTOR(S): Nudler, Evgeny; Rafikova, Ruslan; Rafikova, Olga
PATENT ASSIGNEE(S): New York University, USA
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026345	A1	20040401	WO 2003-US29067	20030917
AU 2003270689	A1	20040408	AU 2003-270689	20030917
US 2004127425	A1	20040701	US 2003-663693	20030917

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-411828P P 20020919
WO 2003-US29067 W 20030917

AB Perfluorocarbons are used to control nitric oxide metabolism, either to inhibit nitric oxide activity or to potentiate the effects of nitric oxide. Perfluorocarbons can be used e.g. to treat hypotension and vasoplegia in septic shock, to protect against myocardial ischemia-reperfusion injury, to treat hypertension, and to provide antiplatelet effects.
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:162309 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 140:205217
TITLE: System for exsanguinous metabolic support of an organ or tissue
INVENTOR(S): Brasile, Lauren
PATENT ASSIGNEE(S): Breonics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S. Ser. No. 849,618.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004038192	A1	20040226	US 2003-443452	20030522
US 6642045	B1	20031104	US 2000-547843	20000412
US 2002012988	A1	20020131	US 2001-849618	20010504
US 6582953	B2	20030624		
WO 2004105484	A1	20041209	WO 2004-US16085	20040521

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-129257P P 19990414
US 2000-547843 A2 20000412
US 2001-849618 A2 20010504
WO 2000-US9894 W 20000413
US 2003-443452 A 20030522

AB An exsanguinous metabolic support system for maintaining an organ or tissue at a near normal metabolic rate is disclosed that employs a warm perfusion solution capable of altering the production of nitric oxide (NO) in an organ or tissue and supporting the metabolism of the organ or tissue at normothermic temps. Perfusion with the solution of the invention can therefore be used to regulate nitric oxide production in situations where it is desirable to do so, e.g. to prevent reperfusion injury. The system also monitors parameters of the circulating perfusion solution, such as pH,

temperature, osmolarity, flow rate, vascular pressure and partial pressure of respiratory gases, and nitric oxide (NO) concentration and regulates them to insure that the organ is maintained under near-physiol. conditions. Use of the system for long-term maintenance of organs for transplantation, for resuscitation and repair of organs having sustained warm ischemic damage, to treat cardiovascular disorders, to prevent reperfusion injury, as a pharmaceutical delivery system and prognosticator of post-transplantation organ function is also disclosed.

L15 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:850188 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 135:111790
TITLE: Compatibility of different colloid plasma expanders with perflubron emulsion: an intravital microscopic study in the hamster
AUTHOR(S): Nolte, Dirk; Pickelmann, Sven; Lang, Michael; Keipert, Peter; Messmer, Konrad
CORPORATE SOURCE: Department of Oral and Maxillofacial Surgery-Regional Plastic Surgery, Ruhr-University of Bochum, Bochum, Germany
SOURCE: Anesthesiology (2000), 93(5), 1261-1270
CODEN: ANESAV; ISSN: 0003-3022
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Perfluorocarbon-based oxygen carriers have been proposed as an adjunct to autologous blood conservation techniques during elective surgery. To date, the effects of perfluorocarbon emulsions at the microcirculatory level have not been studied extensively. In this study the effects of perflubron emulsion on the microcirculation after acute normovolemic hemodilution (ANH) were investigated using different colloid plasma expanders. The dorsal skin fold chamber model and intravital fluorescence microscopy were used for anal. of the microcirculation in the thin striated skin muscle of conscious hamsters (body weight, 40-60 g). Measurements of microvascular perfusion and leukocyte adhesion (n = 6 animals per exptl. group) were made before and at 10, 30, and 60 min after ANH (to hematocrit 0.3) with either 6% hydroxyethyl starch 200/0.6 (HES), 3.5% gelatin, 5% human serum albumin (HSA), or 6% dextran 60 (DX-60) followed by i.v. injection of 3 mL/kg body weight of a 60% weight/volume perfluorocarbon emulsion based on perflubron (perfluorooctyl bromide) emulsified with egg yolk lecithin. Acute normovolemic hemodilution with HES, gelatin, or HSA followed by injection of perflubron emulsion elicited no alterations of local microvascular perfusion or leukocyte-endothelium interaction as assessed in arterioles and postcapillary venules. However, ANH with DX-60 followed by injection of perflubron emulsion led to a significant reduction of erythrocyte velocity

in postcapillary venules and an increase in venular leukocyte sticking that was never observed with DX-60 alone. Conclusions: Hydroxyethyl starch, gelatin, and HSA are compatible with perflubron emulsion in the setting of ANH. Only DX-60 appeared to be incompatible with perflubron emulsion, as evidenced by impairment of capillary perfusion.
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:727886 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 134:247049
TITLE: Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers
AUTHOR(S): Noveck, Robert J.; Shannon, E. J.; Leese, Phillip T.; Shorr, Jolene S.; Flaim, Kathryn E.; Keipert, Peter E.; Woods, Catherine M.
CORPORATE SOURCE: Clinical Research Center, New Orleans, LA, USA
SOURCE: Anesthesia & Analgesia (Baltimore) (2000), 91(4), 812-822
CODEN: AACRAT; ISSN: 0003-2999
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To test the safety of a 2nd-generation perflubron-based emulsion (60% perfluorocarbon [PFC] wt/vol; Oxygent) with a small mean particle size, two parallel, randomized, double-blinded, placebo-controlled studies were conducted in healthy volunteers. The study focused on safety concerning immune function. The subjects received either perflubron emulsion i.v. (1.2 or 1.8 g PFC/kg) or saline. Perflubron emulsion had no effect on delayed hypersensitivity skin reactions, lymphocyte proliferative potential, circulatings Igs, complement activation, or plasma concns. of inflammatory cytokines. The emulsion was generally well tolerated, although there was a dose-dependent increase in minor flu-like symptoms 24 h after perflubron administration. The clin. safety profile of perflubron emulsion supports its continued investigation as a temporary O carrier in surgical patients to reduce exposure to allogeneic blood transfusion.
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:12216 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 130:71307
TITLE: Cosmetic skin or hair care compositions containing

perfluorocarbons infused with carbon dioxide
INVENTOR(S): Penska, Christine; Santhanam, Uma; Habif, Stephan
PATENT ASSIGNEE(S): Chesebrough-Pond's USA Co., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5851544	A	19981222	US 1997-993294	19971218
JP 11228382	A	19990824	JP 1998-342956	19981202
EP 938890	A2	19990901	EP 1998-309869	19981202
EP 938890	A3	20010704		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
IN 190943	A1	20030906	IN 1998-BO781	19981202
CA 2255108	A1	19990618	CA 1998-2255108	19981203
ZA 9811274	A	20000609	ZA 1998-11274	19981209
MX 9810717	A	20020312	MX 1998-10717	19981215
CN 1231173	A	19991013	CN 1998-126971	19981218

PRIORITY APPLN. INFO.: US 1997-993294 A 19971218
AB Cosmetic skin or hair care compns. containing a liquid, inert, hydrophobic fluorocarbon infused with carbon dioxide. The compns. increase blood flow to the skin, thus increasing endogenous oxygen and nutrient delivery to the skin. An oil-in-water cream contained perfluorodecalin infused with carbon dioxide 0.15, mineral oil 4, Brij-56 4, Alfol-16RD 4, triethanolamine 0.75, butane-1,3-diol 3, xanthan gum 0.3, perfume qs, BHT 0.01 and water to 100% by weight
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:803934 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 130:33019
TITLE: Anti-inflammatory agents for prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
INVENTOR(S): Long, David M., Jr.
PATENT ASSIGNEE(S): Alliance Pharmaceutical Corp., USA
SOURCE: U.S., 17 pp., Cont.-in-part of U.S. 5,284,645.
CODEN: USXXAM
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5847009	A	19981208	US 1993-138485	19931015
US 4865836	A	19890912	US 1986-818690	19860114
US 4987154	A	19910122	US 1987-82846	19870805
AU 8939649	A	19910117	AU 1989-39649	19890705
US 5284645	A	19940208	US 1989-417796	19891004
US 5393513	A	19950228	US 1993-100664	19930730
WO 9510306	A1	19950420	WO 1994-US11590	19941014
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9480161	A	19950504	AU 1994-80161	19941014
US 6361792	B1	20020326	US 1998-206805	19981207

PRIORITY APPLN. INFO.: US 1986-818690 A2 19860114
US 1987-82846 A2 19870805
US 1989-417796 A2 19891004
WO 1989-US2948 A 19890705
US 1989-387947 A1 19890824
US 1991-811026 B1 19911219
US 1993-138485 A 19931015
WO 1994-US11590 W 19941014

AB Methods are provided for preventing or ameliorating the transient adverse physiol. response to particulate dispersions (TAPR response) when these dispersions are administered parenterally to a patient. The methods comprise the administration of a prophylactic anti-inflammatory drug prior to administration of the particulate-containing material, and optionally during administration as well. Preferred drugs are cyclooxygenase inhibitors and corticosteroids.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:750094 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 126:26599
TITLE: Increased antioxidant capacity, suppression of free radical damage and erythrocyte aggregation after combined application of alpha-tocopherol and FC-43 perfluorocarbon emulsion in early postburn period in rats
AUTHOR(S): Bekyarova, G.; Yankova, T.; Galunska, B.
CORPORATE SOURCE: Department Pathophysiology, University Medicine Varna,

Varna, 9002, Bulg.
SOURCE: Artificial Cells, Blood Substitutes, and Immobilization Biotechnology (1996), 24(6), 629-641
CODEN: ABSBE4; ISSN: 1073-1199
PUBLISHER: Dekker
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The aim of the present study was to examine the antioxidant capacity, free radical-mediated damage, and erythrocyte aggregation in plasma of rats with thermal skin injury in the early postburn period and to evaluate the effect of treatment with a-tocopherol and FC-43 perfluorocarbon emulsion alone and in combination. Thermal skin injury in rats reduced the antioxidant capacity, enhanced free radical-mediated damage, and erythrocyte aggregation on the 3rd hour after injury. The combined application of a-tocopherol and FC-43 immediately after thermal skin injury in rats increased the plasma antioxidant capacity, decreased free radical-mediated damage of erythrocytes, and suppressed their aggregation on the 3rd hour after the injury.

L15 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:849295 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 123:237830
TITLE: Fluorocarbon-containing oil emulsions as oxygen carriers
INVENTOR(S): von Werner, Konrad; Gross, Udo
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Ger. Offen., 7 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4405627	A1	19950824	DE 1994-4405627	19940222
EP 670159	A1	19950906	EP 1995-102244	19950218
R: CH, DE, FR, GB, IT, LI, NL				

PRIORITY APPLN. INFO.: DE 1994-4405627 A 19940222
OTHER SOURCE(S): MARPAT 123:237830
AB Aqueous emulsions of oils addnl. containing a fluorocarbon (RF)xARH [RF = highly fluorinated alkyl; RH = H, alkyl; A = O, S, (OCH2CH2)p; x = 1-4; p = 1, 2] or an oligomer of the type [Y(CF2)aOb(CH2)cCH:CH2]n (Y = H, F; a = 2-16; b, c = 0, 1; n = 2-4) are useful for O transport in the vascular system,

the dermis, biotechnol., fermentation, and cell culture, as well as for vehicles for drugs and contrast agents and as stds. in blood gas monitoring. Thus, a mixture of 1H-perfluorooctane 30, soybean oil 3.5, and 9% aqueous phospholipid solution to 50 mL was sonicated to a mean particle size of 110 nm and autoclaved at 121⁻ for i.v. administration as an O-transporting medium.

L15 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:465307 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 121:65307
TITLE: Amphiphilic sulfurated, fluorinated and polyglycerol surfactant compounds, cosmetic or pharmaceutical composition containing them, preparation process and vesicles formed
INVENTOR(S): Bollens, Eric; Mahieu, Claude
PATENT ASSIGNEE(S): Fr.
SOURCE: Can. Pat. Appl., 53 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2101620	A1	19940130	CA 1993-2101620	19930729
FR 2694289	A1	19940204	FR 1992-9404	19920729
FR 2694289	B1	19941014		
US 5459165	A	19951017	US 1993-99488	19930727
EP 585157	A1	19940302	EP 1993-401976	19930729
EP 585157	B1	19960320		
R: AT, BE, CH, DE, DK, ES, GB, GR, IE, IT, LI, NL, PT, SE				
JP 06192217	A	19940712	JP 1993-188335	19930729
AT 135686	T	19960415	AT 1993-401976	19930729
ES 2085739	T3	19960601	ES 1993-401976	19930729
US 5591449	A	19970107	US 1995-502463	19950414

PRIORITY APPLN. INFO.: FR 1992-9404 A 19920729
US 1993-99488 A3 19930727
OTHER SOURCE(S): MARPAT 121:65307
AB The title agents Rf(CH2)mSGnH [Rf = perfluorinated C6-20 alkyl radical; m = 0, 1, 2; n = 2-10; G = CH2CH(CH2OH)O, CH(CH2OH)CH2O, CH2CH(O)CH2O, etc.] are useful as surfactants in cosmetic or pharmaceutical compns. Some of the compds. are nonionic amphiphilic lipids capable of forming lamellar vesicles. 1-(F-hexyl)-5,9,10-ol-7-oxa-3-thiodecane (I) was prepared from 2-F-hexylethanethiol and glycidyl ether and

isopropylideneglyceryl. I was used in an antiaging serum.

L15 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:692319 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 121:292319
TITLE: Characterization and mechanism of side-effects of Oxygent HT (highly concentrated fluorocarbon emulsion) in swine
AUTHOR(S): Flaim, S.F.; Hazard, D.R.; Hogan, J.; Peters, R.M.
CORPORATE SOURCE: Alliance Pharmaceutical Corp., San Diego, CA, 92121, USA
SOURCE: Artificial Cells, Blood Substitutes, and Immobilization Biotechnology (1994), 22(4), 1511-15
CODEN: ABSBE4; ISSN: 1073-1199
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Perfluorooctyl bromide is an oxygen-carrying perfluorocarbon presently under development as an artificial blood substitute (OxygentTM HT). Oxygent HT i.v. elicits a mild side-effect profile in man characterized by early onset headache and nausea and delayed onset fever. Early onset flushing has also been observed Species of Artiodactyla are sensitive to particulate injections and demonstrate a transient pulmonary hypertensive response thought to be associated with the large number of pulmonary intravascular macrophages found in these species. Because of this sensitivity, we chose the swine as a model for further investigations. In anesthetized and conscious swine, i.v. Oxygent HT transiently increased mean pulmonary artery pressure (mPAP) and caused flushing. Both effects peaked at 30 min post injection and were resolved by 2 h. Plasma thromboxane B2 (TxB) increased in response to Oxygent HT. Oxygent HT-induced changes in mPAP, flush, and plasma TxB were blocked by aspirin and ibuprofen. Dexamethasone and SQ 29,548 (thromboxane receptor antagonist) blocked the mPAP increase. In conscious swine, Oxygent HT caused a febrile response which was blocked by ibuprofen or dexamethasone. Thus, both early- and late-onset effects of Oxygent HT in swine are blocked by interference with the arachidonic acid cascade. These findings suggest that the 2-phase "flu-like" syndrome induced by Oxygent HT is secondary to the release of products of the arachidonic acid cascade and may be effectively prophylaxed in man with corticosteroids or long plasma half-life cyclooxygenase inhibitors.

L15 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:579293 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 93:179293
ORIGINAL REFERENCE NO.: 93:28399a,28402a
TITLE: A new look at the vapor pressure problem in red cell substitutes

AUTHOR(S): Clark, Leland C., Jr.; Moore, Robert E.; Diver, Sunny; Miller, Marian L.
CORPORATE SOURCE: Children's Hosp. Res. Found., Cincinnati, OH, 45229, USA
SOURCE: International Congress Series (1979), 486(Proc. Int. Symp. Perfluorochem. Blood Substitutes, 4th, 1978), 55-67
CODEN: EXMDA4; ISSN: 0531-5131
DOCUMENT TYPE: Journal
LANGUAGE: English
AB About 30 fluorocarbons, most of them newly-synthesized cyclic perfluorocarbons, such as alkyl-substituted cyclohexanes, were injected i.p. at a dose of 5 mL/kg in mice. Such compds. were found to be transpired at rates from a few to hundreds of nanograms per min. In compds. having the same vapor pressure and mol. weight and containing only C and F great differences in rates of elimination are found. I.p. emulsions were transpired at nearly the same rate as i.v. emulsions. This method makes it possible to evaluate new structures quant. for their rate of transpiration. In addition, the exodus rates of mixts. of known compds. and isomers were measured by this method. Each cyclic and aliphatic fluorocarbon has a characteristic rate at which the vapors from the peritoneal cavity leave. Both chemical structure and vapor tension must be considered when designing fluorocarbon red cell substitutes which must leave the body by transpiration.

=> d his

(FILE 'HOME' ENTERED AT 13:13:20 ON 12 FEB 2008)

FILE 'REGISTRY' ENTERED AT 13:13:40 ON 12 FEB 2008
E PERFLUOROCARBON
L1 26 S E1-E12

FILE 'CAPLUS, BIOSIS, MEDLINE, USPATFULL, EMBASE' ENTERED AT 13:14:28 ON
12 FEB 2008
L2 143119 S L1 OR (PERFLUOR?)
L3 25249 S L2 AND (EMULSION?)
L4 3019 S L3 AND (NERV? OR ENDOCRIN?)
L5 820 S L4 AND (CAPILLAR?)
L6 70 S L5 AND (SKIN(P)CAPILLAR?)
L7 70 DUP REM L6 (0 DUPLICATES REMOVED)
L8 50 S L7 AND (PY<=2005)

FILE 'STNGUIDE' ENTERED AT 13:18:47 ON 12 FEB 2008

FILE 'CAPLUS' ENTERED AT 13:23:48 ON 12 FEB 2008

L9 0 S L8 AND PERFLUORO?

L10 59156 S PERFLUOR?

L11 3000 S L10 AND EMULSION?

L12 125 S L11 AND (SKIN? OR EPIDERM?)

L13 0 S L12 AND (CAPILAR?)

L14 14 S L12 AND BLOOD?

L15 14 DUP REM L14 (0 DUPLICATES REMOVED)